(Q48762317)

15 February 2018

title

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis (English)

1 reference

15 February 2018

0 references

1 reference

1 reference

CHAMPS Study Group

1

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 October 2001

1 reference

15 February 2018

American Journal of Ophthalmology

published in

1 reference

15 February 2018

volume

132

1 reference

15 February 2018

issue

4

1 reference

15 February 2018

page(s)

463-471

1 reference

15 February 2018

Optic neuritis or multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Optic neuritis and multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Magnetic resonance imaging of the brain in patients with acute monosymptomatic optic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Clinical and magnetic resonance imaging in optic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Disseminated lesions at presentation in patients with optic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901209-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(01)01209-0

1 reference

15 February 2018

1 reference

15 February 2018